Eledon Pharmaceuticals (ELDN) Financials

Eledon Pharmaceuticals logo
$1.97 -0.15 (-7.08%)
Closing price 04:00 PM Eastern
Extended Trading
$2.04 +0.07 (+3.55%)
As of 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Eledon Pharmaceuticals

Annual Income Statements for Eledon Pharmaceuticals

This table shows Eledon Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-45 -5.66 -13 -14 -16 -23 -35 -88 -117 -36 -46
Consolidated Net Income / (Loss)
-45 -5.66 -13 -14 -16 -23 -35 -88 -117 -36 -46
Net Income / (Loss) Continuing Operations
-45 -5.66 -13 -14 -16 -23 -35 -88 -117 -36 -46
Total Pre-Tax Income
-45 -5.13 -13 -14 -16 -23 -37 -88 -117 -36 -46
Total Operating Income
-45 -5.13 -13 -14 -16 -18 -37 -88 -43 -71 -83
Total Gross Profit
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
45 5.13 13 14 16 18 37 88 43 71 83
Selling, General & Admin Expense
13 1.94 11 7.24 6.06 10 13 13 13 19 17
Research & Development Expense
33 3.19 2.02 6.82 8.13 6.13 24 27 30 52 66
Total Other Income / (Expense), net
0.17 0.00 0.00 0.00 0.04 -4.75 0.01 0.46 -74 35 38
Other Income / (Expense), net
- - - - 0.04 -4.75 0.01 0.46 -74 35 38
Income Tax Expense
- - - - 0.00 -0.40 -2.35 - 0.00 0.43 0.04
Basic Earnings per Share
($2.01) ($2.46) ($2.30) ($1.56) ($24.42) ($15.72) ($2.33) ($6.16) $0.00 ($0.66) ($0.52)
Weighted Average Basic Shares Outstanding
22.48M 382.75K 4.68M 9.01M 655.53K 1.45M 14.82M 14.29M 0.00 48.54M 81.84M
Diluted Earnings per Share
($2.01) ($2.46) ($2.30) ($1.56) ($24.42) ($15.72) ($2.33) ($6.16) $0.00 ($0.66) ($0.52)
Weighted Average Diluted Shares Outstanding
22.48M 382.75K 4.68M 9.01M 655.53K 1.45M 14.82M 14.29M 0.00 48.54M 81.84M
Weighted Average Basic & Diluted Shares Outstanding
22.48M 382.75K 4.68M 9.01M 655.53K 1.45M 14.82M 13.78M 24.81M 59.88M 75.85M

Quarterly Income Statements for Eledon Pharmaceuticals

This table shows Eledon Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-24 -45 54 -22 -6.50 -11 -17 -12 -39 -32 -3.93
Consolidated Net Income / (Loss)
-24 -45 77 -45 -6.50 -11 -17 -10 -39 -32 -3.93
Net Income / (Loss) Continuing Operations
-24 -45 77 -45 -6.50 -11 -17 -10 -39 -32 -3.93
Total Pre-Tax Income
-24 -45 77 -43 -6.50 -11 -17 -10 -39 -32 -3.93
Total Operating Income
-11 -15 -21 -25 -18 -25 -19 -21 -21 -23 -22
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
11 15 21 25 18 25 19 21 21 23 22
Selling, General & Admin Expense
3.46 4.40 3.99 6.77 4.43 4.46 4.10 3.99 3.98 4.64 3.91
Research & Development Expense
7.41 10 17 18 14 20 15 17 17 18 18
Total Other Income / (Expense), net
-13 -30 97 -19 11 14 1.61 11 -18 -8.76 18
Other Income / (Expense), net
-13 -30 97 -19 11 14 1.61 11 -18 -8.76 18
Basic Earnings per Share
($0.65) ($0.92) $1.05 $0.05 ($0.08) ($0.13) ($0.21) ($0.10) ($0.33) ($0.27) ($0.03)
Weighted Average Basic Shares Outstanding
29.99M 42.28M 51.95M 48.54M 77.13M 77.16M 77.16M 81.84M 112.42M 113.63M 114.72M
Diluted Earnings per Share
($0.65) ($0.92) ($0.28) $1.42 ($0.08) ($0.13) ($0.21) ($0.10) ($0.33) ($0.27) ($0.03)
Weighted Average Diluted Shares Outstanding
29.99M 42.28M 55.48M 48.54M 77.13M 77.16M 77.16M 81.84M 112.42M 113.63M 114.72M
Weighted Average Basic & Diluted Shares Outstanding
38.51M 39.66M 59.74M 59.88M 59.88M 59.88M 59.93M 75.85M 77.19M 81.26M 84.46M

Annual Cash Flow Statements for Eledon Pharmaceuticals

This table details how cash moves in and out of Eledon Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-81 -1.99 16 -4.33 -4.18 105 -29 -28 -52 16 2.26
Net Cash From Operating Activities
-41 -4.92 -15 -12 -14 -15 -29 -28 -40 -47 -62
Net Cash From Continuing Operating Activities
-41 -4.92 -15 -12 -14 -15 -29 -28 -40 -47 -62
Net Income / (Loss) Continuing Operations
-45 -5.66 -13 -14 -16 -23 -35 -88 -117 -36 -46
Consolidated Net Income / (Loss)
-45 -5.66 -13 -14 -16 -23 -35 -88 -117 -36 -46
Amortization Expense
0.07 - - - 0.17 0.18 0.20 0.37 0.37 0.00 0.00
Non-Cash Adjustments To Reconcile Net Income
2.67 0.70 0.63 1.54 3.01 7.82 7.90 56 81 -21 -25
Changes in Operating Assets and Liabilities, net
1.00 0.00 -2.48 0.62 -1.04 -0.40 -2.51 2.74 -4.55 9.48 7.97
Net Cash From Investing Activities
-41 0.00 23 0.00 0.00 11 0.00 0.00 -45 -70 11
Net Cash From Continuing Investing Activities
-41 0.00 23 0.00 0.00 11 0.00 0.00 -45 -70 11
Purchase of Investments
-40 - - - - - - 0.00 -78 -156 -161
Sale and/or Maturity of Investments
- - - - - - - 0.00 33 86 172
Net Cash From Financing Activities
0.51 2.93 7.87 7.56 9.68 110 -0.45 0.00 33 134 54
Net Cash From Continuing Financing Activities
0.51 2.93 7.87 7.56 9.68 110 -0.45 0.00 33 134 54
Issuance of Common Equity
- - 4.75 7.49 9.68 9.00 - 0.00 33 133 54
Other Financing Activities, net
0.46 - 3.12 0.07 0.00 5.36 0.00 - 0.00 0.22 0.23

Quarterly Cash Flow Statements for Eledon Pharmaceuticals

This table details how cash moves in and out of Eledon Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
1.04 20 -19 14 -12 -2.76 -2.07 19 -17 -1.53 -0.95
Net Cash From Operating Activities
-8.74 -7.77 -12 -19 -16 -18 -14 -14 -23 -23 -19
Net Cash From Continuing Operating Activities
-8.74 -7.77 -12 -19 -16 -18 -14 -14 -23 -25 -20
Net Income / (Loss) Continuing Operations
-24 -45 77 -45 -6.50 -11 -17 -10 -39 -32 -3.93
Consolidated Net Income / (Loss)
-24 -45 77 -45 -6.50 -11 -17 -10 -39 -32 -3.93
Non-Cash Adjustments To Reconcile Net Income
15 34 -96 27 -7.89 -10 1.61 -8.39 21 10 -16
Changes in Operating Assets and Liabilities, net
0.27 3.33 6.89 -1.00 -1.68 3.61 1.37 4.74 -4.29 -3.53 0.24
Net Cash From Investing Activities
9.78 -20 -13 -47 3.89 15 12 -20 5.96 23 19
Net Cash From Continuing Investing Activities
9.78 -20 -13 -47 3.89 15 12 -20 5.96 23 19
Purchase of Investments
-13 -36 -34 -73 -32 -27 -33 -69 -43 -16 -9.37
Sale and/or Maturity of Investments
23 16 21 25 36 42 45 49 49 40 29
Net Cash From Financing Activities
0.00 48 5.28 80 0.12 - - 54 0.00 0.09 -0.27
Net Cash From Continuing Financing Activities
0.00 48 5.28 80 0.12 - - 54 0.00 0.09 -0.27
Other Financing Activities, net
0.00 - - - 0.12 - - 0.12 0.00 0.09 -0.27

Annual Balance Sheets for Eledon Pharmaceuticals

This table presents Eledon Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
68 1.20 21 17 11 197 171 93 89 177 169
Total Current Assets
67 1.15 19 14 9.97 116 88 60 56 144 136
Cash & Equivalents
24 1.10 17 13 8.79 114 85 56 4.61 21 23
Short-Term Investments
40 - - - - - - 0.00 46 120 111
Prepaid Expenses
3.21 0.03 1.70 1.30 1.18 1.44 3.51 3.11 5.03 3.55 2.35
Plant, Property, & Equipment, net
0.49 0.03 0.03 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.32 0.02 1.87 2.74 0.96 82 82 33 33 34 33
Other Noncurrent Operating Assets
0.05 0.02 - 0.87 0.96 33 34 33 33 34 33
Total Liabilities & Shareholders' Equity
68 1.20 21 17 11 197 171 93 89 177 169
Total Liabilities
6.25 3.90 1.44 2.53 1.47 6.59 6.55 8.61 82 59 32
Total Current Liabilities
6.16 3.90 1.44 2.53 1.32 2.48 4.40 6.48 3.90 12 18
Accounts Payable
1.21 0.34 0.42 0.69 0.33 1.37 1.81 2.20 0.97 5.83 3.63
Accrued Expenses
4.95 0.11 0.35 1.85 0.81 0.97 2.22 3.91 2.55 5.43 14
Other Current Liabilities
- - - - 0.18 0.14 0.37 0.36 0.38 0.31 0.36
Total Noncurrent Liabilities
0.09 0.00 0.00 0.00 0.14 4.11 2.15 2.14 78 48 14
Noncurrent Deferred & Payable Income Tax Liabilities
- - - - 0.00 4.11 1.75 1.75 1.75 2.18 2.19
Other Noncurrent Operating Liabilities
0.09 - - - 0.14 0.00 0.40 0.38 76 46 12
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - - - - - 56 56 56
Total Equity & Noncontrolling Interests
62 -2.70 19 14 9.47 191 164 84 -48 62 81
Total Preferred & Common Equity
62 -2.70 19 14 9.47 191 164 84 -48 62 81
Total Common Equity
62 -2.72 19 14 9.47 191 164 84 -48 62 81
Common Stock
193 11 47 56 67 271 279 287 271 418 482
Retained Earnings
-131 -14 -28 -42 -58 -80 -115 -203 -319 -356 -401
Accumulated Other Comprehensive Income / (Loss)
-0.06 - - - - - - - 0.00 0.03 0.02

Quarterly Balance Sheets for Eledon Pharmaceuticals

This table presents Eledon Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
96 81 120 115 161 145 130 147 126 107
Total Current Assets
63 48 87 82 128 111 96 114 93 74
Cash & Equivalents
3.67 5.66 26 6.75 8.50 5.74 3.67 6.15 6.80 6.88
Short-Term Investments
56 37 58 71 116 102 90 105 82 63
Prepaid Expenses
3.38 5.12 3.61 3.32 2.84 3.83 2.90 2.49 4.34 4.04
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
33 33 33 33 34 34 34 33 33 33
Other Noncurrent Operating Assets
33 33 33 33 34 34 34 33 33 33
Total Liabilities & Shareholders' Equity
96 81 120 115 161 145 130 147 126 107
Total Liabilities
4.73 96 129 39 47 39 39 46 54 37
Total Current Liabilities
2.90 4.25 6.03 12 9.19 14 14 13 12 12
Accounts Payable
0.47 1.86 2.15 5.86 2.90 5.83 4.63 6.59 3.21 2.84
Accrued Expenses
2.04 2.10 3.61 6.44 5.96 7.55 9.32 6.50 8.19 8.52
Other Current Liabilities
0.40 0.28 0.27 0.19 0.33 0.34 0.35 0.37 0.38 0.34
Total Noncurrent Liabilities
1.84 91 123 26 38 25 25 33 42 25
Noncurrent Deferred & Payable Income Tax Liabilities
1.75 1.75 1.75 1.75 2.18 2.18 2.18 2.19 2.19 2.19
Other Noncurrent Operating Liabilities
0.08 90 121 24 35 23 22 31 40 23
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest
- - - - 56 56 56 56 39 39
Total Equity & Noncontrolling Interests
91 -15 -8.50 76 59 50 35 45 33 31
Total Preferred & Common Equity
91 -15 -8.50 76 59 50 35 45 33 31
Total Common Equity
91 -15 -8.50 76 59 50 35 45 33 31
Common Stock
325 328 379 387 421 424 426 485 505 507
Retained Earnings
-234 -343 -388 -311 -362 -373 -391 -440 -472 -476
Accumulated Other Comprehensive Income / (Loss)
0.00 0.00 0.00 0.10 -0.02 -0.05 0.01 -0.07 -0.11 -0.13

Annual Metrics And Ratios for Eledon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eledon Pharmaceuticals' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
22,584,675.00 22,641,651.00 7,085,414.00 9,422,143.00 12,967,338.00 1,431,316.00 14,306,788.00 13,756,788.00 24,198,130.00 - 59,932,212.00
DEI Adjusted Shares Outstanding
139,411.00 139,763.00 393,634.00 523,452.00 720,408.00 1,431,316.00 14,306,788.00 13,756,788.00 24,198,130.00 - 59,932,212.00
DEI Earnings Per Adjusted Shares Outstanding
-323.41 -40.46 -33.32 -26.87 -22.22 -15.94 -2.41 -6.39 -4.82 - -0.76
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-92.31% 88.70% -157.20% -7.25% -12.67% -45.51% -59.19% -138.90% -32.62% 69.53% -27.49%
EBIT Growth
-92.91% 88.67% -155.87% -7.16% -13.88% -44.99% -58.78% -138.65% -32.48% 69.32% -27.49%
NOPAT Growth
-92.91% 88.67% -155.87% -7.16% -14.16% -15.04% -99.66% -139.86% 51.37% -64.13% -17.96%
Net Income Growth
-93.54% 87.46% -131.94% -7.24% -13.84% -42.47% -51.27% -154.93% -32.48% 68.95% -26.07%
EPS Growth
44.17% 87.46% 6.50% 32.17% -13.84% 35.63% 85.18% -164.38% 100.00% 84.14% 21.21%
Operating Cash Flow Growth
-95.24% 88.06% -203.49% 20.40% -16.51% -9.78% -90.07% 1.69% -39.06% -19.59% -31.88%
Free Cash Flow Firm Growth
-92.27% 81.63% -104.62% 21.29% -12.77% -753.27% 67.78% 63.20% 495.45% -271.43% -17.54%
Invested Capital Growth
-28.03% 85.14% 677.69% -29.27% -55.66% 11,235.46% 3.61% -64.92% -258.04% 49.79% 115.62%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
-11.61% 88.77% -171.75% -21.36% 3.78% -43.06% -9.14% -126.77% 20.01% -65.43% 42.56%
EBIT Q/Q Growth
-11.89% 88.71% -172.02% -21.33% 2.73% -42.56% -9.14% -125.74% 19.96% -64.31% 42.56%
NOPAT Q/Q Growth
-11.89% 88.71% -150.41% -21.33% 2.49% -13.39% -8.98% -126.01% 52.93% -25.54% 3.71%
Net Income Q/Q Growth
-11.94% 87.50% -174.69% -21.24% 2.62% -8.36% -9.18% -129.15% 19.53% -67.01% 42.83%
EPS Q/Q Growth
-12.29% 87.50% -190.91% -26.83% 2.62% 16.78% -9.39% -129.00% 100.00% 75.65% -136.36%
Operating Cash Flow Q/Q Growth
-6.23% 60.67% -9.76% -6.65% 8.76% -94.98% 0.77% -0.97% 0.88% -26.34% 7.28%
Free Cash Flow Firm Q/Q Growth
0.00% 79.96% -197.28% -6.42% 13.95% -9.67% -0.60% 59.39% 303.10% -1,196.98% -38.88%
Invested Capital Q/Q Growth
-69.81% 92.14% 47.70% -24.04% -73.59% 6.13% 3.20% -63.07% -238.35% -933.19% 246.70%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 110.28% 99.96% 100.04% 100.00% 98.26% 93.61% 100.00% 100.00% 101.21% 100.08%
Interest Burden Percent
99.62% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-54.58% -19.16% -156.61% -82.87% -133.66% -22.80% -19.46% -70.89% -255.03% -57.73% -35.79%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% -544.70% -502.21% -947.10% -230.04% -36.73% -19.66% 0.00% 0.00% -2,432.67%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-54.58% -19.16% -156.43% -82.87% -133.66% -22.80% -19.46% -70.89% -99.61% -57.73% -20.15%
Return on Equity Simple (ROE_SIMPLE)
-73.05% 209.29% -67.43% -97.05% -169.16% -11.97% -21.04% -104.49% 0.00% -30.63% 0.00%
Net Operating Profit after Tax (NOPAT)
-32 -3.59 -9.18 -9.84 -11 -13 -26 -62 -30 -49 -58
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-15.80% -6.67% -52.51% -27.90% -43.88% -16.08% -8.74% -36.91% -160.80% 13.82% 9.26%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - 62.08% -41.82% -71.87%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-45 -5.13 -13 -14 -16 -23 -37 -88 -117 -36 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-45 -5.09 -13 -14 -16 -23 -37 -88 -116 -35 -46
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
3.19 0.00 1.48 1.04 0.79 0.12 0.38 0.37 0.00 2.08 1.12
Price to Tangible Book Value (P/TBV)
3.19 0.00 1.64 1.19 0.79 0.16 0.55 0.37 0.00 2.08 1.12
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 5.33 1.38 0.00 0.00 0.00 0.00 0.00 0.00 3.73
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.16 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 -1.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.03 -1.05 -0.89 -0.89 -0.91 -0.61 -0.56 -0.57 -1.18 -1.53 -1.07
Leverage Ratio
1.06 1.17 1.32 1.12 1.17 1.04 1.04 1.06 1.99 2.13 1.36
Compound Leverage Factor
1.06 1.17 1.32 1.12 1.17 1.04 1.04 1.06 1.99 2.13 1.36
Debt to Total Capital
0.00% 462.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 462.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 2.55% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 772.67% 0.00% 40.72%
Common Equity to Total Capital
100.00% -365.23% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -672.67% 100.00% 59.28%
Debt to EBITDA
0.00 -0.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 -0.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 -0.96 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 -0.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
15.08 -30.34 9.08 -1.75 -8.18 1.74 4.71 -3.32 -8.32 -0.09 -1.70
Noncontrolling Interest Sharing Ratio
0.00% 0.03% 0.11% 0.00% 0.00% 0.00% 0.00% 0.00% 60.94% 0.00% 43.70%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
10.90 0.30 13.19 5.63 7.54 46.57 20.07 9.19 14.41 12.42 7.40
Quick Ratio
10.38 0.28 11.97 5.12 6.65 45.99 19.28 8.71 13.12 12.11 7.27
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-31 -5.72 -12 -9.21 -10 -89 -29 -11 42 -71 -84
Operating Cash Flow to CapEx
-7,298.41% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-2.50 -0.37 2.15 1.52 0.67 76 79 28 -44 -22 3.44
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.55 2.13 2.52 -0.63 -0.85 76 2.76 -51 -72 22 25
Enterprise Value (EV)
133 24 11 2.10 -1.27 -92 -22 -25 48 106 13
Market Capitalization
197 22 29 15 7.52 22 63 31 44 246 90
Book Value per Share
$2.73 ($0.12) $2.75 $1.54 $0.73 $133.16 $11.46 $6.12 ($2.00) $1.98 $1.35
Tangible Book Value per Share
$2.73 ($0.12) $2.48 $1.34 $0.73 $99.17 $8.06 $6.12 ($2.00) $1.98 $1.35
Total Capital
62 0.75 19 14 9.47 191 164 84 7.21 118 137
Total Debt
0.00 3.45 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-64 2.33 -17 -13 -8.79 -114 -85 -56 -51 -140 -133
Capital Expenditures (CapEx)
0.57 -0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.95 -0.42 0.26 -1.23 -0.14 -1.05 -0.89 -3.37 1.13 -8.03 -16
Debt-free Net Working Capital (DFNWC)
61 0.70 18 12 8.65 113 84 53 52 132 117
Net Working Capital (NWC)
61 -2.75 18 12 8.65 113 84 53 52 132 117
Net Nonoperating Expense (NNE)
13 2.07 3.93 4.22 4.78 9.89 8.70 26 86 -13 -13
Net Nonoperating Obligations (NNO)
-64 2.33 -17 -13 -8.79 -114 -85 -56 -51 -140 -133
Total Depreciation and Amortization (D&A)
0.18 0.04 0.02 0.01 0.18 0.18 0.20 0.37 0.37 0.36 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($325.62) ($272.16) ($41.40) ($28.08) ($24.48) ($15.72) ($2.33) ($6.16) $0.00 ($0.75) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding
139.66K 139.76K 522.61K 524.13K 892.75K 14.31M 14.31M 14.29M 0.00 48.54M 81.84M
Adjusted Diluted Earnings per Share
($325.62) ($272.16) ($41.40) ($28.08) ($24.48) ($15.72) ($2.33) ($6.16) $0.00 ($0.75) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding
139.66K 139.76K 522.61K 524.13K 892.75K 14.31M 14.31M 14.29M 0.00 48.54M 81.84M
Adjusted Basic & Diluted Earnings per Share
($325.62) ($272.16) ($41.40) ($28.08) ($24.48) ($15.72) ($2.33) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
138.79K 139.72K 259.87K 500.30K 655.53K 1.45M 14.82M 13.78M 0.00 59.88M 75.85M
Normalized Net Operating Profit after Tax (NOPAT)
-32 -3.59 -9.18 -9.84 -9.93 -11 -26 -28 -30 -49 -58
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.30% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Eledon Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Eledon Pharmaceuticals' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
24,813,130.00 77,013,228.00 79,311,404.00 - 59,881,775.00 59,881,775.00 59,881,775.00 59,932,212.00 75,851,722.00 77,187,823.00 81,261,152.00
DEI Adjusted Shares Outstanding
24,813,130.00 77,013,228.00 79,311,404.00 - 59,881,775.00 59,881,775.00 59,881,775.00 59,932,212.00 75,851,722.00 77,187,823.00 81,261,152.00
DEI Earnings Per Adjusted Shares Outstanding
-0.95 -0.58 0.69 - -0.11 -0.19 -0.27 -0.20 -0.51 -0.41 -0.05
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-121.26% 32.41% 884.46% -47.89% 72.51% 75.02% -122.68% 76.44% -500.85% -182.01% 77.47%
EBIT Growth
-119.37% 32.51% 877.01% -47.72% 72.51% 75.02% -122.68% 76.44% -500.85% -182.01% 77.47%
NOPAT Growth
2.17% -40.06% -161.65% -138.89% -65.28% -70.55% 34.91% 13.01% -17.91% 7.54% -13.64%
Net Income Growth
-119.37% 31.71% 877.01% -48.23% 72.51% 75.02% -122.68% 76.59% -500.85% -182.01% 77.47%
EPS Growth
13.33% 66.42% 15.15% 256.04% 87.69% 85.87% 25.00% -108.40% -312.50% -107.69% 85.71%
Operating Cash Flow Growth
11.92% 5.44% 3.93% -107.94% -83.73% -127.85% -23.01% 25.79% -40.80% -28.02% -31.10%
Free Cash Flow Firm Growth
79.74% 156.45% -62.54% -160.75% -176.47% -197.60% -198.40% -3.52% 75.78% 99.24% -34.45%
Invested Capital Growth
-303.45% -422.39% -106.72% 49.79% 82.11% 98.33% -10.03% 115.62% -3.20% -984.63% 106.05%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
19.16% -90.03% 271.40% -156.11% 85.30% -72.69% -55.66% 40.36% -274.81% 18.95% 87.57%
EBIT Q/Q Growth
19.41% -90.03% 271.40% -156.28% 85.30% -72.69% -55.66% 40.36% -274.81% 18.95% 87.57%
NOPAT Q/Q Growth
-5.14% -33.43% -102.04% 15.71% 27.26% -37.68% 22.90% -12.66% 1.41% -7.97% 5.23%
Net Income Q/Q Growth
21.49% -90.03% 271.40% -157.97% 85.44% -72.69% -55.66% 40.16% -273.55% 18.95% 87.57%
EPS Q/Q Growth
28.57% -41.54% 69.57% 543.75% -106.72% -62.50% -61.54% 52.38% -230.00% 18.18% 88.89%
Operating Cash Flow Q/Q Growth
4.27% 11.06% -51.39% -61.33% 15.42% -10.29% 18.27% 2.67% -60.47% -0.29% 16.30%
Free Cash Flow Firm Q/Q Growth
21.51% 41.18% -87.92% -393.23% -52.94% -80.21% 87.82% -208.49% 64.22% 94.31% -2,039.76%
Invested Capital Q/Q Growth
-31.20% -59.94% 97.68% -933.19% 53.26% 85.03% -52.20% 246.70% -408.77% -57.32% 100.85%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 103.00% 100.00% 100.00% 100.00% 100.34% 100.00% 100.00% 100.00%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-430.86% -237.39% -25.89% -57.73% -38.15% 30.03% -95.49% -35.79% -72.68% -110.71% -105.72%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,432.67% 0.00% 0.00% -44,741.69%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-430.86% -237.39% -25.89% -57.73% -16.87% 12.88% -63.67% -20.15% -35.03% -51.82% -43.48%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-7.61 -10 -21 -17 -13 -17 -13 -15 -15 -16 -15
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-35.87% -44.85% 141.48% -28.58% 7.25% 6.38% -4.79% 3.36% -20.51% -15.91% 13.78%
Return On Investment Capital (ROIC_SIMPLE)
51.66% 119.41% -26.97% -14.63% -21.35% -34.40% -37.75% -18.55% -33.12% -48.49% -49.26%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-24 -45 77 -43 -6.50 -11 -17 -10 -39 -32 -3.93
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-24 -45 77 -43 -6.50 -11 -17 -10 -39 -32 -3.93
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.00 0.00 1.30 2.08 3.45 3.22 4.39 1.12 5.22 9.21 6.68
Price to Tangible Book Value (P/TBV)
0.00 0.00 1.30 2.08 3.45 3.22 4.39 1.12 5.22 9.21 6.68
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 11.08 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 9.02% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.73 0.00 0.00 1,231.95
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 7.32 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 7.32 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.15 0.21 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-1.49 -1.69 -0.82 -1.53 -1.68 -1.96 -1.03 -1.07 -1.10 -1.10 -1.01
Leverage Ratio
2.72 2.49 1.26 2.13 2.42 2.72 1.46 1.36 1.43 1.52 1.47
Compound Leverage Factor
2.72 2.49 1.26 2.13 2.42 2.72 1.46 1.36 1.43 1.52 1.47
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 48.61% 52.53% 61.17% 40.72% 55.44% 54.17% 55.89%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 51.39% 47.47% 38.83% 59.28% 44.56% 45.83% 44.11%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-5.94 -4.46 0.68 -0.23 0.21 -0.55 -1.50 -1.01 -1.23 -1.92 -2.32
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 55.78% 57.11% 33.33% 43.70% 51.80% 53.19% 58.88%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
11.30 14.48 6.53 12.42 13.91 8.12 6.74 7.40 8.44 7.90 6.30
Quick Ratio
10.09 13.88 6.26 12.11 13.60 7.84 6.53 7.27 8.25 7.53 5.95
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
78 111 13 -39 -60 -108 -13 -41 -14 -0.83 -18
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-58 -92 -2.13 -22 -10 -1.54 -2.35 3.44 -11 -17 0.14
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-86 -121 -34 22 47 91 -0.21 25 -0.33 -15 2.49
Enterprise Value (EV)
8.25 18 21 106 134 110 117 13 178 254 175
Market Capitalization
51 102 99 246 203 162 155 90 234 304 206
Book Value per Share
($0.59) ($0.22) $1.92 $1.98 $0.98 $0.84 $0.59 $1.35 $0.59 $0.43 $0.38
Tangible Book Value per Share
($0.59) ($0.22) $1.92 $1.98 $0.98 $0.84 $0.59 $1.35 $0.59 $0.43 $0.38
Total Capital
-15 -8.50 76 118 115 106 91 137 100 72 70
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-43 -84 -78 -140 -125 -108 -93 -133 -111 -89 -70
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.87 -2.41 -9.17 -8.03 -6.35 -9.89 -11 -16 -11 -7.45 -7.66
Debt-free Net Working Capital (DFNWC)
44 81 69 132 119 98 82 117 100 81 62
Net Working Capital (NWC)
44 81 69 132 119 98 82 117 100 81 62
Net Nonoperating Expense (NNE)
16 35 -97 27 -6.08 -6.10 4.11 -4.59 24 16 -11
Net Nonoperating Obligations (NNO)
-43 -84 -78 -140 -125 -108 -93 -133 -111 -89 -70
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.06) $1.05 $0.05 $0.00 ($0.13) ($0.21) ($0.10) ($0.33) ($0.27) ($0.03)
Adjusted Weighted Average Basic Shares Outstanding
0.00 42.28M 51.95M 48.54M 0.00 77.16M 77.16M 81.84M 112.42M 113.63M 114.72M
Adjusted Diluted Earnings per Share
$0.00 ($1.06) ($0.32) $1.42 $0.00 ($0.13) ($0.21) ($0.10) ($0.33) ($0.27) ($0.03)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 42.28M 55.48M 48.54M 0.00 77.16M 77.16M 81.84M 112.42M 113.63M 114.72M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 39.66M 59.74M 59.88M 0.00 59.88M 59.93M 75.85M 77.19M 81.26M 84.46M
Normalized Net Operating Profit after Tax (NOPAT)
-7.61 -10 -14 -17 -13 -17 -13 -15 -15 -16 -15
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Eledon Pharmaceuticals (NASDAQ: ELDN) remains a clinical-stage biotechnology company with no reported revenue. Its financial profile is therefore driven primarily by research spending, investment income and equity financing rather than commercial operations.

In the second quarter of 2026, Eledon reported a net loss of $31.6 million, or $0.27 per diluted share, compared with a $39.0 million loss in the first quarter. However, the loss was substantially wider than the $11.2 million loss reported in the restated second quarter of 2025. Research and development spending increased to $18.2 million from $17.2 million sequentially and $20.3 million in the year-earlier quarter.

The company ended Q2 2026 with $89.0 million in cash and short-term investments, down from $111.1 million at the end of Q1 2026. Operating activities consumed $22.7 million during the quarter, indicating that Eledon continues to rely on its investment portfolio and potential future financing to fund development activities.

  • Substantial liquidity remains: Cash and short-term investments totaled approximately $89.0 million at June 30, 2026, providing an important funding base for clinical development.
  • Strong short-term balance-sheet coverage: Current assets of $93.1 million exceeded current liabilities of $11.8 million by a wide margin, implying a current ratio of roughly 7.9 times.
  • Quarterly net loss improved sequentially: The Q2 2026 net loss narrowed to $31.6 million from $39.0 million in Q1, while other expense declined from $17.8 million to $8.8 million.
  • Liabilities remain relatively limited compared with liquid assets: Total liabilities were $54.1 million at quarter-end, although this comparison should account for the company’s redeemable noncontrolling interest.
  • Investment activity is a major source of cash-flow volatility: Eledon purchased $16.3 million of investments and received $39.5 million from investment sales or maturities in Q2 2026. Investment income and realized gains or losses can materially affect reported earnings without reflecting operating progress.
  • Historical results include unusual and restated items: The large profit reported in Q3 2024 was primarily driven by $97.5 million of other income, while several 2024 and 2025 figures were later restated. Comparisons should focus on recurring operating cash burn rather than isolated quarterly earnings.
  • The company has not generated revenue: Reported revenue has remained at zero throughout the periods provided, leaving Eledon dependent on financing, investment returns and potential future product success.
  • Operating cash burn remains high: Cash used in operating activities increased to $22.7 million in Q2 2026 from $17.7 million in Q2 2025. The company has reported negative operating cash flow in every quarter supplied.
  • Research spending continues to rise: R&D expense of $18.2 million in Q2 2026 was higher than the prior quarter and represented most of the company’s $22.9 million in operating expenses.
  • Shareholder dilution and accumulated losses are significant risks: Weighted-average basic shares increased to 113.6 million in Q2 2026 from 77.2 million in Q1 2025, while retained earnings stood at a deficit of $471.9 million. Additional equity financing could further dilute existing shareholders.

Overall, Eledon’s balance sheet still provides a meaningful liquidity cushion, but the company’s financial trend remains dependent on clinical progress. With no revenue, persistent operating losses and quarterly cash use above $20 million, investors should closely monitor cash runway, clinical milestones and the terms of any future financing.

11/16/26 10:02 PM ETAI Generated. May Contain Errors.

Eledon Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Eledon Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Eledon Pharmaceuticals' net income appears to be on a downward trend, with a most recent value of -$45.62 million in 2025, falling from -$45.09 million in 2015. The previous period was -$36.18 million in 2024. See Eledon Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Eledon Pharmaceuticals' total operating income in 2025 was -$83.25 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $83.25 million

Over the last 10 years, Eledon Pharmaceuticals' total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

In the past 12 quarters, Eledon Pharmaceuticals' cash and equivalents has ranged from $3.67 million in Q3 2023 to $26.04 million in Q2 2024, and is currently $6.88 million as of their latest financial filing in Q3 2026.

Eledon Pharmaceuticals had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2015.

Over the last 10 years, Eledon Pharmaceuticals' book value per share changed from 2.73 in 2015 to 1.35 in 2025, a change of -50.5%.



Financial statements for NASDAQ:ELDN last updated on 11/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners